Bristol Myers Squibb
A Bristol Myers Squibb research and development facility in Lawrence, New Jersey (corporate headquarters since July 2023) | |
| Bristol Myers Squibb | |
| Formerly | Bristol-Myers Company (1887–1989) |
| Company type | Public |
| Industry | Pharmaceuticals |
| Predecessors | Squibb Corporation (1858–1989) |
| Founded | 1887 |
| Founders | |
| Headquarters |
|
Area served | Worldwide |
Key people | |
| Revenue | US$48.3 billion (2024) |
| US$−8.4 billion (2024) | |
| US$−8.9 billion (2024) | |
| Total assets | US$92.6 billion (2024) |
| Total equity | US$16.3 billion (2024) |
Number of employees | 34,100 (2024) |
| Website | bms |
| Footnotes / references | |
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (28% of 2024 revenues); nivolumab (Opdivo), used to treat certain types of cancer (19% of 2024 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (12% of 2024 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2024 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (8% of 2024 revenues); ipilimumab (Yervoy), to treat cancer (5% of 2024 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (4% of 2024 revenues). In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.
BMS's primary research and development (R&D) sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton), Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey; Redwood City, California; and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts; Braine-l'Alleud, Belgium; Tokyo, Japan; Hyderabad; Bangalore, India and Wirral, United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers).